USE OF AT-1 RECEPTOR ANTAGONIST OR AT-2 RECEPTOR MODULATOR FOR TREATING DISEASES ASSOCIATED WITH AN INCREASE OF AT-1 OR AT-2 RECEPTORS

The present invention relates to solid dosage forms comprising valsartan as an active agent and pharmaceutically acceptable additives/carriers suitable for the preparation of the solid dosage forms.